In the BioHarmony Drug Report Database

"Preview" Icon

Lumateperone

Caplyta (lumateperone) is a small molecule pharmaceutical. Lumateperone was first approved as Caplyta on 2019-12-20. It is used to treat schizophrenia in the USA. It is known to target 5-hydroxytryptamine receptor 2A, sodium-dependent serotonin transporter, and D(2) dopamine receptor. Caplyta’s patents are valid until 2039-08-30 (FDA).

 

Trade Name

 

Caplyta
 

Common Name

 

lumateperone
 

ChEMBL ID

 

CHEMBL3306803
 

Indication

 

schizophrenia
 

Drug Class

 

Antianxiety agents/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)

Image (chem structure or protein)

Lumateperone structure rendering